TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report)’s stock price rose 4.1% during mid-day trading on Tuesday . The company traded as high as $146.35 and last traded at $146.25. Approximately 253,620 shares were traded during trading, a decline of 67% from the average daily volume of 762,765 shares. The stock had previously closed at $140.51.
Analyst Upgrades and Downgrades
TMDX has been the subject of a number of recent research reports. TD Cowen lifted their price objective on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Morgan Stanley lifted their price objective on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. Stephens started coverage on TransMedics Group in a research note on Tuesday, June 4th. They set an “overweight” rating and a $151.00 price objective for the company. Cantor Fitzgerald started coverage on TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 target price for the company. Finally, Canaccord Genuity Group lifted their target price on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.88.
TransMedics Group Stock Up 3.9 %
The company has a quick ratio of 8.76, a current ratio of 9.72 and a debt-to-equity ratio of 3.18. The company has a market cap of $4.81 billion, a P/E ratio of -429.35 and a beta of 1.94. The company has a fifty day moving average of $127.33 and a 200 day moving average of $98.02.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, topping the consensus estimate of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The company had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. During the same quarter in the previous year, the company posted ($0.08) earnings per share. TransMedics Group’s revenue was up 132.9% compared to the same quarter last year. On average, research analysts anticipate that TransMedics Group, Inc. will post 0.77 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, Director David Weill sold 1,193 shares of TransMedics Group stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $141.65, for a total value of $168,988.45. Following the completion of the sale, the director now owns 10,732 shares of the company’s stock, valued at $1,520,187.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other TransMedics Group news, Director David Weill sold 1,193 shares of the business’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $141.65, for a total transaction of $168,988.45. Following the completion of the sale, the director now owns 10,732 shares of the company’s stock, valued at $1,520,187.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen Gordon sold 15,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $74.01, for a total value of $1,110,150.00. Following the sale, the chief financial officer now directly owns 23,299 shares of the company’s stock, valued at approximately $1,724,358.99. The disclosure for this sale can be found here. Insiders sold 290,501 shares of company stock valued at $33,268,189 over the last 90 days. Company insiders own 7.00% of the company’s stock.
Institutional Trading of TransMedics Group
Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in TransMedics Group by 1.3% during the first quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock valued at $139,680,000 after purchasing an additional 23,979 shares during the period. Eventide Asset Management LLC lifted its position in shares of TransMedics Group by 7.4% in the fourth quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock valued at $78,475,000 after acquiring an additional 68,884 shares in the last quarter. Sandhill Capital Partners LLC lifted its position in shares of TransMedics Group by 4.2% in the fourth quarter. Sandhill Capital Partners LLC now owns 763,201 shares of the company’s stock valued at $60,239,000 after acquiring an additional 30,591 shares in the last quarter. First Light Asset Management LLC lifted its position in shares of TransMedics Group by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after acquiring an additional 136,217 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of TransMedics Group by 3.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company’s stock valued at $53,977,000 after acquiring an additional 21,737 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.
About TransMedics Group
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.